Home › Intestinal Failure › NCT05879835
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
Safety and Effectiveness of 4% Tetrasodium Ethylenediaminetetraacetic Acid Catheter Lock Solution in Preventing Central Venous Catheter Occlusions in Children With Intestinal Failure: A Randomized Controlled Trial
Who can join
4 Weeks – 18 Years · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Patients managed by the intestinal rehabilitation program at one of the participating centers. 2. Diagnosis of intestinal failure defined as need for PN support for \>60 days in previous 74 days for primary intestinal disease (short bowel syndrome, primary motility disorder, mucosal enteropathy). 3. Expectation of the treating physician that the patient will require PN for at least 6 months following enrollment. 4. Age less than 18 years at diagnosis but greater than 4 weeks chronological age or 40 weeks estimated gestational age, whichever is greater. 5. Stable TPN cycling (4 hours off TPN minimum per day) enabling home TPN management 6. Presence of a tunneled central venous catheter (CVC), port-a-catheter, or peripherally inserted central catheter (PICC). 7. Clinical stability for at least 4 weeks and no acute medical comorbidities. 8. A minimum dwell time of 4 consecutive hours daily. 9. Care provider willing to provide informed consent to participate in the trial and willing to comply with randomization and study protocol. Exclusion Criteria: 1. A temporary CVC (jugular or femoral) or peripheral catheter. 2. Patients receiving long-term PN, but not due to a primary intestinal disorder (i.e., oncology patients or premature neonates on PN due to intestinal immaturity). 3. Known hypersensitivity, allergy, or reaction to EDTA. 4. Pregnancy or nursing mother. 5. Participation in another investigational device or drug trial within 30 days prior to enrollment (unless approved by the principal investigators of the trial). 6. Severe coagulopathy (platelets \<50,000, or INR \> 1.5). 7. Diagnosis of immunodeficiency disorder. 8. Unstable medical condition requiring hospital admission 9. Received antibiotic therapy for CLABSI within last 14 days.
About the study
A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).
What is being tested
- KiteLock 4% Sterile Catheter Lock Solution (device)
- Heparin Lock Solution (device)
Sponsor: SterileCare Inc. · Participants: 124 · Started: Jun 21, 2024
Contact the study team
- Joanne Greco · Phone: 6472006232
Official record on ClinicalTrials.gov — NCT05879835
Locations in the U.S.
| Massachusetts | Boston Children's Hospital, Boston |
| Nebraska | University of Nebraska Medical Center, Omaha (Not yet recruiting) |
| New York | Nyph/Cumc, New York |
| North Carolina | Duke University Medical Center, Durham |
| Ohio | Cincinnati Children's Hospital Medical Center, Cincinnati Nationwide Children's Hospital, Columbus |
| Texas | Cook Children's Health Care System, Fort Worth |
| Washington | Seattle Children's Hospital, Seattle |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.